Published in BMC Neurol on November 21, 2015
Meta-Analysis of Differential Connectivity in Gene Co-Expression Networks in Multiple Sclerosis. Int J Mol Sci (2016) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. Mult Scler (2013) 5.40
Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci (2008) 5.15
The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics (2012) 4.48
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol (2009) 2.39
Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler (2003) 2.24
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology (2004) 2.04
A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain (2009) 1.69
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol (2008) 1.59
A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics (2012) 1.55
Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry (2012) 1.54
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One (2008) 1.43
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Interferon-beta mechanisms of action in multiple sclerosis. Neurology (2010) 1.40
Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci (2007) 1.31
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol (2005) 1.26
Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain (2003) 1.22
Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol (2001) 1.20
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J (2012) 1.04
Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. Mol Neurobiol (2013) 0.96
IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol (2008) 0.95
Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods (2007) 0.91
Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol (2009) 0.89
Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev (2013) 0.86
Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med (2013) 0.86
Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. PLoS One (2013) 0.81
An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients. Curr Pharm Des (2012) 0.79